Clinical trials
Clear Cell Renal Cell Carcinoma clinical trials
Below are recruiting clear cell renal cell carcinoma clinical trials, each written for real people, not researchers. We’re tracking 159 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07489495RecruitingPhase 3
Belzutifan and zanzalintinib for advanced kidney cancer
This study tests two new drugs, belzutifan and zanzalintinib, for people with advanced kidney cancer that has not responded well to other treatments. The goal is to see if the combination slows down cancer growth.
Marietta, GeorgiaAges 18 years+ - NCT07187778RecruitingPhase 2
Kidney cancer treatment before surgery
This trial tests two drugs, alone or together, given before surgery to shrink kidney cancer tumors. It aims to see which approach works best for patients with intermediate- to high-risk clear cell renal cell carcinoma.
Houston, TexasAges 18 years+ - NCT07123090RecruitingPhase 2
Triple Therapy for Advanced Kidney Cancer
This trial tests a combination of three drugs—sasanlimab (immunotherapy), palbociclib (targeted therapy), and axitinib (VEGF inhibitor)—for people with advanced kidney cancer who have not had prior treatment. It aims to see if this triple therapy is safe and effective.
Boston, MassachusettsAges 18 years+ - NCT05361720RecruitingPhase 2
Genetic test to match treatment for advanced kidney cancer
This study looks at genetic (RNA) testing of kidney cancer tissue to help choose the best drug treatment. It may help guide therapy for people with advanced or metastatic clear cell kidney cancer who are starting treatment for the first time.
Duarte, CaliforniaAges 18 years+ - NCT05256225RecruitingPhase 3
Adding Herceptin medicines to chemo for HER2-positive endometrial cancer
This Phase 3 trial tests whether adding Herceptin Hylecta or Phesgo to standard chemotherapy works better than chemotherapy alone for HER2-positive serous endometrial cancer or carcinosarcoma. It may help by improving how well treatment controls or shrinks the cancer.
Birmingham, AlabamaAges 18 years+ - NCT07620574Enrolling by invitationPhase 3
Long-Term Study Continuing Cancer Treatment from Previous Trial
This study lets people who were in an earlier Exelixis cancer treatment trial continue receiving the same treatment if it's still helping them. It's designed to see how safe and effective the treatment is over a longer period.
Bay Shore, New YorkAges Any age - NCT05287945RecruitingPhase 1/Phase 2
Orellanine for kidney cancer patients on dialysis
This early-stage study tests orellanine to treat advanced kidney cancer that has spread (metastatic clear-cell or papillary type). It may help by shrinking or controlling cancer, and by seeing whether the treatment is safe and tolerable in people already on chronic dialysis.
Orange, CaliforniaAges 18 years+ - NCT07195682RecruitingPhase 1
Study of an experimental drug for advanced kidney cancer
This trial tests a new drug (BMS-986506) for people with advanced kidney cancer (clear cell renal cell carcinoma). It aims to see if the drug is safe and effective. Depending on the part of the study, participants may have had prior treatments or be newly diagnosed.
Boston, MassachusettsAges 18 years+ - NCT05706129RecruitingPhase 1/Phase 2
Testing targeted imaging and therapy for advanced solid tumors
This early-phase study tests two radioactive medicines that first help doctors see tumors and, in some parts of the study, treat them. It may help people with advanced, hard-to-remove cancers that have a specific tumor marker (CA IX).
MelbourneAges 18 years+ - NCT07239596RecruitingPhase 1/Phase 2
Study of three drugs for advanced kidney cancer
This trial tests a combination of three drugs (SHR-8068, adebrelimab, and another anti-tumor drug) for people with advanced kidney cancer (clear cell type). The goal is to see if the combination works better than current treatments.
Beijing, Beijing MunicipalityAges 18–75 - NCT07187869RecruitingPhase 1
Cabozantinib plus nivolumab for kidney cancer with bone spread
This study tests whether adding a drug called cabozantinib to standard nivolumab treatment helps fight kidney cancer that has spread to bone. It aims to understand how the bone environment changes during treatment.
Houston, TexasAges 18 years+ - NCT07188896RecruitingPhase 2
Immunotherapy combinations for advanced kidney cancer
This trial tests a combination of immunotherapy drugs (fianlimab, cemiplimab, and possibly ipilimumab) compared to another immunotherapy combo (ipilimumab + nivolumab) for people with advanced kidney cancer who have not had previous treatment. The goal is to see which combination works better.
Washington D.C., District of ColumbiaAges 18 years+ - NCT06794229RecruitingPhase 2
Zanzalintinib plus nivolumab before surgery for advanced kidney cancer
This trial tests two drugs—zanzalintinib and nivolumab—given before surgery to shrink advanced or hard-to-remove kidney tumors. The goal is to make the tumor easier to remove and improve outcomes.
St Louis, MissouriAges 18 years+ - NCT06321250RecruitingPhase 1
Study of a new tablet for advanced kidney cancer
This study tests a new tablet (JMKX003948) for people with advanced clear cell kidney cancer. It aims to see if the drug is safe and how well it works.
BeijingAges 18 years+ - NCT07179770RecruitingPhase 1
Belzutifan and imaging in advanced kidney cancer
This trial tests a new drug called belzutifan combined with a special imaging agent (89Zr-DFO-girentuximab) to see how they affect PET scans in people with advanced clear cell kidney cancer. It may help doctors better understand the cancer and guide treatment.
New York, New YorkAges 18 years+ - NCT07645690RecruitingEarly Phase 1
CD70 CAR-T Cell Therapy for Advanced Kidney Cancer
This early-stage trial tests a new type of cell therapy called CD70 CAR-T for advanced kidney cancer (clear cell renal cell carcinoma) that has spread or cannot be surgically removed. The therapy uses cells from your own immune system that are genetically modified to recognize and attack cancer cells.
BeijingAges 18–75 - NCT07615348RecruitingPhase 2
CD70 imaging to guide treatment breaks in advanced kidney cancer
This trial tests whether a special type of imaging scan (CD70-targeted PET/CT) can help doctors safely pause treatment in patients with advanced kidney cancer who respond well to standard immunotherapy and targeted therapy. The goal is to reduce unnecessary treatment while keeping the cancer controlled.
Nanjing, JiangsuAges 18 years+ - NCT05768464RecruitingPhase 2
Surgery aftercare for non-clear kidney cancer at high risk
This Phase 2 trial studies an after-surgery treatment for people with non-clear types of kidney cancer who are at high risk of coming back. It aims to lower the chance of recurrence by giving extra therapy after your tumor is completely removed.
Nanjing, JiangsuAges 18–75 - NCT07097935RecruitingPhase 1/Phase 2
Study of HS-10516 combo therapy for advanced kidney cancer
This trial tests a new combination therapy for people with advanced clear cell kidney cancer that has progressed after at least one prior treatment. It aims to see if adding HS-10516 to standard care can help shrink tumors or slow the disease.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07002346RecruitingPhase 3
Immunotherapy and bevacizumab for advanced ovarian clear cell cancer
This trial tests a combination of an immunotherapy drug (QL1706) and a targeted therapy (bevacizumab) for women with newly diagnosed advanced ovarian clear cell carcinoma. The goal is to see if this combination works better than standard treatment after surgery.
Wuhan, HubeiAges 18–75 - NCT07744932RecruitingPhase 2
Radiation plus drug combo for kidney cancer that has spread a little
This trial tests a combination of targeted radiation, an oral drug (axitinib), and an immunotherapy (toripalimab) for people with kidney cancer that has spread to a few spots. It aims to see if this combo helps control the cancer longer.
Shijiazhuang, HebeiAges 18 years+ - NCT06819293RecruitingPhase 1
IB-T101 injection for advanced kidney cancer
This trial tests an experimental injection called IB-T101 for people with advanced clear cell renal cell carcinoma, a type of kidney cancer. It aims to see if the treatment is safe and possibly effective.
Wuhan, HubeiAges 18 years+ - NCT06004336RecruitingPhase 2
Maintenance therapy after radiation for limited spread kidney cancer
This trial tests whether giving a maintenance medication (pembrolizumab) after targeted radiation helps keep kidney cancer that has spread to a few spots (5 or fewer) from growing. You would receive radiation to each spot and then be randomly assigned to receive either the medication or a placebo (inactive substance) for up to about 2 years.
Houston, TexasAges 18 years+ - NCT06428708RecruitingEarly Phase 1
PSMA PET scan for metastatic kidney cancer
This trial uses a special PET scan called PSMA to see if it can better detect kidney cancer that has spread. It may help find tumors that other scans miss.
London, OntarioAges 18 years+
Hear when a new Clear Cell Renal Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Clear Cell Renal Cell Carcinoma trials by city
Studies with a site in or near these metro areas.
Clear Cell Renal Cell Carcinoma trials by state
Studies with a site anywhere in these states.
Common questions
- Are there clinical trials for clear cell renal cell carcinoma?
- Yes. Clin2 currently lists 159 recruiting clear cell renal cell carcinoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a clear cell renal cell carcinoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a clear cell renal cell carcinoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.